Congress trade2 different filers disclosed ZTS within 90 days. Disclosed 49 days after the transaction; reported as an official range, not an exact amount.
Loading…
ZTS · NYSE · Pharmaceuticals
Pharmaceuticals company based in Parsippany, New Jersey.
Last close, Oct 1, 2026
$69.10
Adjusted for splits and dividends
Last 12 months
-53.0%
S&P 500 +14.3% over the same dates
Market value
$28.6B
Last close × shares outstanding
Bets against the stock: 17.4M shares sold short (4.2% of shares outstanding), -10.5% vs the previous count, 3.8 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$9.47B
+2.3% vs the year before
Net income, fiscal 2025
$2.67B
As reported in the annual filing
Shares outstanding
413M
As of Jul 31, 2026
In fiscal 2025 the company spent $3.23B buying back its own shares. Cash actually paid, from its cash-flow statement.
2 different filers disclosed ZTS within 90 days. Disclosed 49 days after the transaction; reported as an official range, not an exact amount.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
2 different filers disclosed ZTS within 90 days. Disclosed 36 days after the transaction; reported as an official range, not an exact amount.
2 different filers disclosed ZTS within 90 days. Disclosed 36 days after the transaction; reported as an official range, not an exact amount.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 48.4% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 42.5%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
A securities lawsuit naming the company as a defendant was filed on May 27, 2026 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., 1:26-cv-04401Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
31 certified in FY2026 Q3, vs 56 a year earlier. 31 positions in total, median offered wage $105K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Authorization of Emergency Use for Three Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
Notice · Food and Drug Administration
New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor; Change of Sponsor Address
Final rule · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
BlackRock, Inc.
Schedule 13G: passive · filed Jul 30, 2026 · 37.7M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 30.3M shares
Vanguard Portfolio Management
Schedule 13G: passive · filed Apr 29, 2026 · 24.1M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Top officer leaving
“Departure of Wetteny Joseph, Executive Vice President and Chief Financial Officer On July 31, 2026, the Company entered into a letter agreement (the “Letter Agreement”) with Wetteny Joseph setting forth the terms of his departure from the Company.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Last 12 months, adjusted daily closes
Adjusted close went from $146.95 on Oct 1, 2025 to $69.10 on Oct 1, 2026 (-53.0%). Disclosed trades in the last 12 months: 3 insider purchases, 2 insider sales, 6 Congress purchases, 5 Congress sales. 1 group of purchases by several insiders within a few days.
Congress trade